

MRI-guided Tx strategy not superior for rheumatoid arthritis

6 February 2019



(HealthDay)—A magnetic resonance imaging (MRI)-guided treat-to-target strategy is not associated with improved disease activity remission rates for patients with rheumatoid arthritis (RA) in clinical remission, according to a study published in the Feb. 5 issue of the *Journal of the American Medical Association*.

Signe Møller Bisgaard, M.D., Ph.D., from Slagelse Hospital in Denmark, and colleagues conducted a two-year multicenter trial at nine hospitals involving 200 <u>patients</u> with RA in clinical remission (disease activity score in 28 joints-C-reactive protein [DAS28-CRP]

APA citation: MRI-guided Tx strategy not superior for rheumatoid arthritis (2019, February 6) retrieved 25 September 2022 from <u>https://medicalxpress.com/news/2019-02-mri-guided-tx-strategy-superior-rheumatoid.html</u>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.